Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00859)
Name
Baricitinib
Synonyms    Click to Show/Hide the Synonyms of This API
Baricitinib; 1187594-09-7; INCB028050; olumiant; LY3009104; 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; INCB 028050; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile; INCB-028050; UNII-ISP4442I3Y; Baricitinib (LY3009104, INCB028050); LY-3009104; ISP4442I3Y; LY 3009104; 1187594-09-7 (free base); LY3009104 (phosphate);INCB028050 (phosphate); C16H17N7O2S; 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-; Baricitinib [USAN:INN]; INCB 28050; Olumiant (TN); 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-; 3JW; 2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE; cc-652; MLS006011247; SCHEMBL871150; Baricitinib (JAN/USAN/INN); Baricitinib (LY3009104); GTPL7792; CHEMBL2105759; AMMD00005; CHEBI:95341; DTXSID30152228; EX-A413; QCR-197; HMS3651L17; HMS3672M15; HMS3747G21; AOB87724; BCP04686; ABP001023; BDBM50021656; MFCD21608464; NSC799357; s2851; ZINC73069247; AKOS022186127; AKOS025401933; AM81232; BCP9000380; CCG-268312; CS-0724; DB11817; DS-7641; NSC-799357; PB27275; SB10845; NCGC00345839-01; NCGC00345839-14; AC-27404; AK143352; HY-15315; SMR004703006; BCP0726000031; AB0035958; Baricitinib (INCB28050, LY3009104); FT-0775037; SW220096-1; Y0439; D10308; S-7686; J-503551; Q4860707; (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile; {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile; INCB-028050; ; ; LY-3009104; ; ; 2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
Clinical Status
Approved
PubChem CID
44205240
Formula
C16H17N7O2S
Canonical SMILES
CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChI
1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
InChIKey
XUZMWHLSFXCVMG-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=44205240"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 371.4 Topological Polar Surface Area 129
XlogP -0.5 Complexity 678
Heavy Atom Count 26 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 7
Full List of Drug Formulations (DFMs) Containing This API
          Baricitinib 1 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Croscarmellose Sodium; Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Ferric Oxide; Lecithin (Soya); Polyethylene Glycol; Polyvinyl Alcohol; Talc; Titanium Dioxide
                   Dosage Form Tablet
                   Company Eli Lilly And
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [1]
Polyvinyl alcohol DIG Info Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
Soybean lecithin DIG Info Albendazole monooxygenase (IC50 = 6.61 mg.mL-1) [4]
Polyethylene glycol 4000 DIG Info Albendazole monooxygenase (Inhibition ratio < 40 %) [4]
          Baricitinib 2 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Croscarmellose Sodium; Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Ferric Oxide; Lecithin (Soya); Polyethylene Glycol; Polyvinyl Alcohol; Talc; Titanium Dioxide
                   Dosage Form Tablet
                   Company Eli Lilly And
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [1]
Polyvinyl alcohol DIG Info Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
Soybean lecithin DIG Info Albendazole monooxygenase (IC50 = 6.61 mg.mL-1) [4]
Polyethylene glycol 4000 DIG Info Albendazole monooxygenase (Inhibition ratio < 40 %) [4]
References
1 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.
2 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
3 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.
4 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.